Pharma, Medical Devices and Life Sciences in the UAE
In the UAE, EDE regulates medical products: pharma, devices, CDMO, distribution and healthtech each enter differently. Healthcare delivery is a separate page.
The UAE is localising pharmaceutical and medical-product manufacturing, with a new federal regulator for medical products, industrial incentives and government-procurement demand. A pharma manufacturer, a medical-device company, a CDMO and a distributor each enter, and are regulated, differently; healthcare providers and hospitals are covered on a separate page.
The UAE has made pharmaceuticals and life sciences a priority of its industrial strategy, driven by population and insurance growth, a push for drug security and import substitution, and the national investment companies anchoring biologics and contract-manufacturing capacity. The pharmaceutical and medical-products regime was overhauled in 2024-25 through the creation of the Emirates Drug Establishment, and the country's free zones host an established international healthcare and pharmaceutical cluster. For a foreign investor the opportunity is real, but it is not one market: pharma manufacturing, medical devices, CDMO, distribution, clinical R&D, healthcare delivery and healthtech each have a different regulator, pathway, location and market-access structure. This page sets out the routes and the entry.
At a glance
- Pharmaceuticals, biotech and medical devices are priority sectors of the UAE's industrial strategy, driven by drug security and import substitution.
- The Emirates Drug Establishment is a new federal regulator for medical products and pharmaceutical establishments — marketing authorisations, GMP, facility licensing, pharmacovigilance and import/export. Healthcare delivery (hospitals, clinics, diagnostics, professionals) remains emirate-regulated by DHA in Dubai, DoH in Abu Dhabi and other authorities, and is covered in depth on our dedicated page, Hospitals & Healthcare Delivery in the UAE.
- The opportunity spans pharma manufacturing, biologics and CDMO, medical devices and diagnostics, import and distribution, clinical R&D, healthcare delivery and digital health — each with its own pathway.
- Free zones — Dubai Science Park, JAFZA, the Abu Dhabi clusters — host an established international healthcare and pharma base and offer full foreign ownership, with a 0% corporate-tax rate available only on qualifying income for a Qualifying Free Zone Person (non-qualifying income is taxed at 9%).
- In-Country Value is a procurement preference where the customer is a government health system — not a guaranteed purchase order, and not a substitute for product approval, tender qualification and clinical acceptance.
- The UAE is positioned as a manufacturing-and-export base for the wider Gulf, MENA and Africa region.
The UAE life-sciences opportunity
The UAE's life-sciences ambition sits within its broader industrial strategy, which names pharmaceuticals, biotechnology and medical equipment as priority sectors, and it is reinforced by deep, long-horizon capital — the national investment companies are anchoring biologics and contract-manufacturing capacity. Demand is driven by population and insurance growth and by a deliberate drug-security and import-substitution policy, and the country's ports, free zones and trade agreements position it as a manufacturing-and-export base for the surrounding region. For a foreign entrant the opportunity is genuine, but it runs through a specific regulator and pathway that depend on which part of the sector the business is in. These positions are current to 2026; confirm the current position at the time of decision.
EDE and the regulatory split: medical products vs healthcare delivery
The UAE's pharmaceutical and medical-products regime has moved toward federal consolidation through the Emirates Drug Establishment. That does not mean the whole healthcare sector has one regulator. EDE is central for medicines, medical products, pharmaceutical establishments, marketing authorisations, GMP, import and export, and pharmacovigilance. Healthcare delivery — hospitals, clinics, diagnostics, healthcare professionals and clinical facilities — remains regulated through the competent emirate-level health authorities, including DHA in Dubai and DoH in Abu Dhabi. The provider side (operating, licensing or acquiring hospitals, clinics and diagnostics, and the healthcare M&A market) is covered on our dedicated page, Hospitals & Healthcare Delivery in the UAE (hospitals healthcare delivery); this page covers medical products.
The transition is recent. With effect from 29 December 2025, the Ministry of Health and Prevention transferred a defined set of pharmaceutical and medical-product services — reported as around 44 core functions, including marketing authorisations, import and export, GMP certification, facility licensing and pharmacovigilance — to EDE, which now administers them under Federal Decree-Law No. 38 of 2024; the Ministry retains community and compounding pharmacies and certain narcotics-control functions. As the regime is still bedding in, the practical state of any specific service should be confirmed at the time of filing.
Which part of the sector are you entering?
Healthcare, pharma and life sciences are several regulated businesses, and the regulator, the pathway and the structure follow which one a company is in.
The starting point is the product, the regulator, the pathway and the market — domestic, government, export or regional.
| Entry route | Typical foreign investor | Main legal issue |
|---|---|---|
| Pharma manufacturing | Generics, branded, biologics, CDMO | EDE facility licence, GMP, product approval |
| Medical devices | Device manufacturer / distributor | Device registration, conformity, authorised representative |
| Importer / distributor / MAH | Foreign pharma or device company | Establishment licence, import/export, agency / distribution |
| CDMO / toll manufacturing | Contract manufacturer | Quality agreements, technology transfer, GMP, liability |
| Clinical R&D / labs | CRO, diagnostics, testing, research | Facility licence, ethics, data, emirate health authority |
| Healthcare delivery | Clinic, hospital, diagnostics centre | DHA / DoH / emirate licensing; provider depth on the Hospitals & Healthcare Delivery page |
| Digital health / healthtech | Telemedicine, AI diagnostics, platforms | Health-authority approval, data protection, advertising |
Regulatory pathway: facility, GMP and product registration
For medical products, the EDE route runs through facility licensing, GMP readiness and product registration / marketing authorisation. These must be sequenced carefully, and the exact order and filings should be confirmed for the product and the establishment type — manufacturer, CDMO, importer, distributor or marketing-authorisation holder each file differently, and importers and distributors need their own establishment licences. The pathway should be mapped from the outset, because it drives the facility, the timeline and the cost.
Medical devices, diagnostics and healthtech
Medical devices and diagnostics are a separate entry route from pharmaceuticals. A foreign device company may manufacture in the UAE, but many first enter through device registration with the Emirates Drug Establishment, an authorised representative, an importer or distributor, and hospital or public-procurement supply contracts. The legal work usually covers device classification, registration, conformity documentation, import permissions, distribution rights, warranties, after-sales service, recalls and quality obligations.
Healthtech and digital-health businesses add another layer. Telemedicine, AI-enabled diagnostics, remote monitoring, healthcare platforms and digital therapeutics may require approval from the relevant health authority, data-protection analysis, cybersecurity controls, advertising review and clear allocation of clinical responsibility. They should not be treated as ordinary software businesses merely because the technology is digital.
Free zone or mainland
A free-zone entity — in Dubai Science Park, JAFZA or an Abu Dhabi cluster — gives full foreign ownership and duty-free import and re-export, and can access the 0% corporate-tax rate where it qualifies as a Qualifying Free Zone Person on qualifying income (other income is taxed at 9%); it suits export and regional manufacturing. A mainland company sells directly into the UAE market and the public health system, takes healthcare-delivery licensing, and can optimise its In-Country Value position for government procurement, within the corporate-tax system. Many manufacturers use a free-zone base for production and export with a mainland route for domestic sales and distribution; healthcare delivery is generally a mainland activity. A free-zone pharma company selling into the mainland must address import, distribution, product registration, VAT and customs, and whether a mainland distributor or sales entity is needed.
ICV, public procurement and localisation
In-Country Value is a procurement preference mechanism, not a guaranteed purchase order. It can matter where the customer is a government health system, public hospital, national procurement body or government-linked buyer, which use ICV scoring to favour locally-manufactured medicines and higher domestic value-add. It should be designed into the manufacturing and localisation plan, but it does not replace product approval, tender qualification, pricing and clinical acceptance. Where the public system is the intended channel, the ICV position is built into the structure from the outset.
Market access after approval
For pharmaceuticals and medical devices, regulatory approval is only the first gate. A product still needs market access: pricing or reimbursement analysis where applicable, distributor appointment, public-tender qualification, hospital formulary or procurement access, promotion and advertising compliance, post-market surveillance, pharmacovigilance, recall procedures and quality obligations. A UAE manufacturing or distribution structure should therefore be built not only to obtain approval, but to sell into the intended channel — private hospitals, pharmacies, public procurement, export markets or regional distributors.
Gulf, MENA and Africa export base, and the corridor
Much of the UAE life-sciences case rests on its position as a base to manufacture and export across the Gulf, the Middle East, North Africa and Africa, served by its ports, free zones and trade agreements, with the fast-growing regional pharmaceutical market as the prize. For corridor groups, India and the UAE play complementary roles, as independent decisions: India is one of the world's largest pharmaceutical manufacturers and a vast market, while the UAE offers a regulated, export-oriented manufacturing and distribution base for the surrounding region. A group can manufacture at scale in India and run regional manufacturing, finishing, distribution and market access through the UAE, structuring the holding and the cross-border flows accordingly. The India life-sciences opportunity is addressed in the India pages and the corridor work.
How a foreign company enters
The vehicle is a free-zone or mainland company, or both, chosen by the route and the market — the science parks and pharma free zones for manufacturing, R&D and export; the mainland for direct domestic supply, distribution and clinical delivery. The entry then layers on the applicable regulatory pathway — the EDE licensing sequence for medicines, the device-registration route for medical devices, or the emirate health-authority licensing for delivery — the In-Country Value positioning for public-system sales, and the distribution and market-access arrangements. Above the operating entity, groups often place a holding vehicle in ADGM or DIFC. Substance, the qualifying-free-zone-income conditions, and the technology, licensing and transfer-pricing position are the recurring structural points. The structure follows the product and the regulator.
Legal workstreams for a UAE life-sciences entry
A UAE life-sciences entry brings several workstreams together. The legal work usually covers:
- choosing the free-zone or mainland vehicle and the location — Dubai Science Park, JAFZA, an Abu Dhabi cluster or mainland;
- the EDE pathway — facility licence, GMP certification and product registration / marketing authorisation — sequenced for the establishment type;
- for medical devices, classification, registration, conformity documentation, authorised-representative or distributor arrangements, and after-sales and recall obligations;
- the emirate health-authority licensing (DHA, DoH or other) for clinical, diagnostic and delivery activities, and professional licensing;
- for healthtech, the health-authority approval, data-protection, cybersecurity and advertising position, and the allocation of clinical responsibility;
- market access — pricing or reimbursement where applicable, tender qualification, distributor appointment, formulary access, pharmacovigilance and post-market obligations;
- the In-Country Value positioning for public-health-system procurement;
- the free-zone licence, ownership, qualifying-income and customs position, and the ADGM or DIFC holding structure;
- technology, product and process licensing, royalty and transfer-pricing documentation; and
- the corridor structure where the group also operates in India or elsewhere.
Where this goes wrong
- Assuming one regulator covers the whole sector — EDE governs medical products and pharmaceutical establishments, while hospitals, clinics, diagnostics and professionals are emirate-regulated by DHA, DoH and others.
- Treating life sciences as one decision, when manufacturing, devices, CDMO, R&D, delivery and healthtech follow different pathways.
- Starting construction or marketing before mapping the EDE facility, GMP and product-registration sequence for the establishment type.
- Treating product approval as the finish line, when pricing, tender qualification, distribution, formulary access and pharmacovigilance decide whether it sells.
- Overstating In-Country Value as guaranteed demand, rather than a procurement preference that still requires approval, tendering and clinical acceptance.
- Choosing free zone or mainland before identifying the market — export, UAE-domestic or public-system — or leaving licensing, substance and transfer-pricing until after the facility is committed.
- Treating the free-zone 0% as automatic, when it applies only to qualifying income of a Qualifying Free Zone Person — and, for a multinational group with EUR 750 million-plus revenue, the 15% Domestic Minimum Top-up Tax overrides it from January 2025.
How ATB Corporate helps
ATB advises foreign pharmaceutical, medical-device, life-science and digital-health investors entering the UAE, matched to the business and its regulator — manufacturing, devices, CDMO, distribution, R&D, delivery or healthtech. We work the free-zone or mainland vehicle and location; the EDE licensing sequence, the device-registration route, or the emirate health-authority licensing; the market-access plan — pricing, tendering, distribution, formulary and pharmacovigilance; the In-Country Value positioning for public-system sales; the qualifying-income, holding and substance structure; and the technology and transfer-pricing position. For groups also operating in India, the structure is designed across the India-UAE corridor and the regional export base. The point is to align the regulator, the pathway, the structure, the ICV position and the market-access route with the product.
Healthcare & Life Sciences — Answered
No. EDE regulates medical products, pharmaceutical establishments, marketing authorisations, GMP, pharmacovigilance and import and export. Healthcare-delivery businesses such as hospitals, clinics, diagnostics centres and professionals are regulated by the relevant emirate-level health authorities, including DHA in Dubai and DoH in Abu Dhabi.
Through a free-zone or mainland entity, then the EDE pathway — facility licence, GMP certification and product registration / marketing authorisation, sequenced for the establishment type. A free-zone base (Dubai Science Park, JAFZA, an Abu Dhabi cluster) suits export and regional manufacturing; a mainland route suits direct UAE and public-system sales, where the In-Country Value position matters.
Yes. Medical devices involve classification, device registration, conformity documentation, authorised-representative or distributor arrangements, import permissions, after-sales obligations and post-market surveillance. The pathway is different from medicines.
Yes, but the structure must address import, distribution, product registration, VAT and customs, the Qualifying-Free-Zone-Person tax treatment, and whether a mainland distributor or sales entity is needed.
No. The 0% rate applies only to the qualifying income of a Qualifying Free Zone Person meeting the UAE corporate-tax conditions; other income is taxed at 9%. And a pharmaceutical or device business in a multinational group with EUR 750 million-plus consolidated revenue is within the UAE's 15% Domestic Minimum Top-up Tax from January 2025, whatever the free-zone position.
No. Companies also need market access: pricing or reimbursement where applicable, tender qualification, distributor arrangements, hospital or pharmacy channels, advertising compliance and post-market obligations.
Yes, for manufacturing and most activities, in free zones and on the mainland. Healthcare-delivery licensing (hospitals, clinics, diagnostics) is handled by the emirate health authorities and is usually a mainland activity, and is covered in depth on Hospitals & Healthcare Delivery in the UAE. The free-zone-versus-mainland choice follows whether the market is export, UAE-domestic or the public health system.
Drug-security and import-substitution policy, national investment companies anchoring biologics and contract manufacturing, a federal regulator for medical products, free-zone full foreign ownership and a 0% corporate-tax rate on qualifying income for a Qualifying Free Zone Person, In-Country-Value procurement preference for public demand, and a position to manufacture and export across the Gulf, MENA and Africa.
EDE governs medical products while delivery stays emirate-regulated, and the 0%/9% line and ICV are won in the structure, not the licence.
Licensing, approvals and any tax treatment are decided by the authorities on the facts. Talk to our team when you are ready.
Get in touch